Clinical trial · Observational
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Women With Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is one of the most common malignant tumor in women. About 60% of breast cancer patients are still in premenopausal status at the time of diagnosis in China. It is a multicenter prospective observational study. We will collect basic information, medical history, chemotherapy-related adverse reactions, and the results of hormone, blood lipid, and bone density test before, during and after adjuvant or neoadjuvant chemotherapy. The aim of the study is to evaluate the effect of chemotherapy on ovarian function and fertility and the protective effect of GnRHa. In addition, the collected information of the subjects are analyzed to provide suggestions for the relevant prevention strategy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GnRH analogue | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- exposure group
- description
- exposed to some factors
- interventionNames
- Drug: GnRH analogue
- label
- control group
- description
- not exposed to some factors
Primary outcomes (1)
- measure
- Pregnancy outcome
- timeFrame
- 5 years
- description
- The number of patients reporting pregnancy and attempting pregnancy
Secondary outcomes (1)
- measure
- Rate of ovarian failure
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Informed consent form has been signed. 2. Breast cancer patients whose age is ≥ 18 years old and have been diagnosed by histological examination. 3. Plan for adjuvant or neoadjuvant chemotherapy Exclusion Criteria: 1. Postmenopausal women who are defined by any of the following: * Previous bilateral oophorectomy; * Age ≥ 60 years old; * Age \<60 years old, menopause at least 12 months, and follicle stimulating hormone \[FSH\] and estradiol levels in the postmenopausal range. 2. Those who have already received adjuvant or neoadjuvant chemotherapy. 3. Those who have chemotherapy contraindications. 4. Those who have any mental condition that prevents the understanding of the contents of this study and can't provide the complete information required.
References
Publications (0)
Data not yet available